E!115695, ARCHER, Tada Medical AB
| Reference number | |
| Coordinator | Tada Group AB |
| Funding from Vinnova | SEK 4 818 388 |
| Project duration | September 2021 - December 2023 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
AM-ReLink is a combination of two ground-breaking innovations in widely different fields. The goal achieved during the course of the project is to develop AM-ReLink as a basis for a product family of self-cleaning safety connectors to prevent the loss of venous catheters through dislodgement accidents, patient injury and HAI (healthcare-associated infections) in patients undergoing infusion therapy. The product is now ready for the clinical phase.
Expected long term effects
Infusion therapy is the most common invasive treatment in modern healthcare. Unfortunately, up to 36% of treatments are interrupted due to the catheter accidentally being torn from the patient´s vein. This leads to patient injury, increased plastic waste, leakage of medicines and increased risk of care-related infections. Based on the estimated cost to AM-ReLink and our sales forecast, the introduction of our product would result in a cumulative cost saving for the EU and our customers in Europe and the US of €2.1 billion.
Approach and implementation
Project ARCHER has been implemented as six work packages. WP 1: Product system specification. WP 2: Coating procedure maturation. WP 3: Connector maturation. WP 4: Pre-clinical documentation. WP 5: Dissemination and exploitation. Och WP 6: Project management. The project has lasted over 28 months, and the work has been evenly distributed between a Swedish and a Norwegian party who together represent the entire consortium.